Avid Bioservices Inc (CDMO)

[entdoc]

jbainseky and thurly, I am not certain on what statistical basis you are drawing your conclusions. Can you elaborate? These numbers have been crunched backward, forward, and upside down, and without a visible, clear-cut margin, which appears do-able and reasonable to me, it would be lunacy to front this PR. Respectfully requesting clarification. I understand the post-hoc consideration, which I am sure has been cleared (and precedented) with FDA, and agree w. jbainseky about importance of other trials, but it is clear, at least to me, that the NSCLC numbers will be usable.